Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report

Curtit, Elsa; Thiery-Vuillemin, A.; Nguyen, Thierry; Heyd, Bruno; Pivot, Xavier; Martino, Vincent Di; Borg, Christophe

doi:10.1200/jco.2010.32.6785

Cited by 46 publications

(50 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sorafenib therapy did not achieve a complete response in 299 patients in the Sorafenib Hepatocellular Carcinoma Assessment Randomized Protocol (SHARP) study or 150 patients in the Asian Pacific study; the partial response rates were 2.0% and 3.3%, respectively (6,7). Only a few studies have reported a complete response in HCC patients receiving sorafenib treatment (8)(9)(10)(11)(12)(13)(14)(15)(16). We listed these in order of the time to cessation (Table).…”

Section: Discussionmentioning

confidence: 99%

A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma

et al. 2013

View full text Add to dashboard Cite

The response rate and overall survival after sorafenib administration in patients with advanced hepatocellular carcinoma are unsatisfactory. We herein present the case of a 65-year-old man with multiple lung metastases of hepatocellular carcinoma. Because the patient had liver cirrhosis of Child-Pugh B accompanied by pancytopenia, sorafenib administration was initiated at a dose of 400 mg daily. Although he received sorafenib for only 21 days, the patient exhibited complete regression of the tumors. There was no clinical evidence of recurrence without the administration of anticancer treatment. It is unique that short-term sorafenib treatment achieved a complete response.

show abstract

Section: Discussionmentioning

confidence: 99%

A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…However, there were no cases of complete response (CR) among the 449 patients treated with sorafenib in these trials [3,4]. As far as we are aware, there have been few reports of patients achieving CR when treated with sorafenib alone [5,6,7,8,9,10,11,12]. …”

Section: Introductionmentioning

confidence: 99%

Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report

et al. 2011

View full text Add to dashboard Cite

Sorafenib, an oral multikinase inhibitor, has demonstrated clinical efficacy in patients with advanced hepatocellular carcinoma (HCC). However, in the SHARP trial (Sorafenib HCC Assessment Randomized Protocol trial) and the Asia-Pacific trial (conducted in the Asia-Pacific region), no cases of complete response (CR) were reported. Thereafter, only a relatively small number of CR cases were reported worldwide for sorafenib therapy. We herein report a case of CR in a patient treated with sorafenib for 4 months. The patient had advanced HCC with multiple lung metastases, and there has been no recurrence after 8 months following cessation of administration. To our knowledge, this is the first time a female treated with sorafenib alone for HCC has had a CR.

show abstract

“…The partial response (PR) rate in the sorafenib group was 2.0 vs. 1.0% (SHARP) and 3.3 vs. 1.3% (Asia-Pacific) compared with the placebo group (6,7). Only ten case reports of advanced HCC revealing a complete response (CR)/PR to sorafenib monotherapy are present in the literature, published between 2008 and 2011 (Table I) (14)(15)(16)(17)(18)(19). In a multicenter study published in 2014 by Shiba et al, only 18 of 3,047 (0.6%) patients who were administered sorafenib monotherapy at institutions belonging to the Liver Cancer Study Group of Japan obtained a CR (20).…”

Section: Discussionmentioning

confidence: 99%

Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis

Calistri

Cordopatri

Nardi

et al. 2017

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Hepatocellular carcinoma (HCC) is the principal primary liver tumor, representing the third largest cause of cancer-associated death worldwide. The actual reference standard systemic treatment for advanced HCC is represented by sorafenib, a multi-targeted orally active small-molecule tyrosine kinase inhibitor. Sorafenib has exhibited a good general safety profile in multiple clinical trials. However, adverse drug-associated events are common, occasionally severe, and special attention should be paid to cardiovascular adverse events, particularly in patients with risk factors or known heart disease. In the present study, the case of a patient with no known cardiovascular risk factors affected by highly enhancing advanced HCC in cirrhotic liver, who died during successful sorafenib monotherapy, is reported.

show abstract

Complete Histologic Response Induced by Sorafenib in Advanced Hepatocellular Carcinoma: A Case Report

Cited by 46 publications

References 7 publications

A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma

A Complete Response Induced by 21-day Sorafenib Therapy in a Patient with Advanced Hepatocellular Carcinoma

Complete Response of Advanced Hepatocellular Carcinoma with Multiple Lung Metastases Treated with Sorafenib: A Case Report

Sudden cardiac death in a patient with advanced hepatocellular carcinoma with good response to sorafenib treatment: A case report with literature analysis

Contact Info

Product

Resources

About